||The Providence Journal - "Scientists report success in trial of drug to fight Alzheimer's disease" – Breaking news report following the publication of major research news for Alzheimer’s treatment. In a study published in a top scientific journal, Nature, a team of study authors including Dr. Stephen Salloway, director of the Memory and Aging Program at Butler, report favorable findings for a new drug to treat Alzheimer’s. Aducanumab, a novel human antibody, has demonstrated the ability to decrease the amount of amyloid plaque in the brains of patients with Alzheimer’s disease, and slow the rate of cognitive decline. These exciting preliminary results are now being further tested in two current Phase III clinical trials.
||The Providence Journal - "In war on Alzheimer's, R.I.'s Butler Hospital is leading the charge" – This feature story first seen on the front page of the journal, looks at the current affairs in the war on Alzheimer’s disease, and ranks Dr. Stephen Salloway, director of Butler’s Memory and Aging Program, as a general. The in-depth coverage includes articles and accompanying photos and videos that delve into the variety of efforts of Butler’s Memory and Aging Program. A broad spectrum of clinical trials and initiatives that bring the program into collaborations both locally and globally, speak to the committed effort within the Memory and Aging Program to lead a charge toward finding effective treatments for Alzheimer’s.
Also reported by:
Journal EDITORIAL – “Editorial: R.I. battles Alzheimer's”
NBC Channel 10 – “Health Check: Alzheimer's disease treatment”
ABC Channel 6 – “A breakthrough clinical trial, giving hope to
patients with Alzheimer's”
TIME - "An Alzheimer’s Drug Shows Serious Promise”
Science News – “New Alzheimer’s drug shows promise in small trial”
Huffington Post –
“New Drug Clears Abnormal Brain Proteins Tied To
Fox News – “Drug shows promise in reducing abnormal brain
proteins linked to Alzheimer’s”
– “Rhode Island’s role in promising new Alzheimer’s
American – “Alzheimer's Drug Shows Promise in Small Trial”
Science – “Alzheimer’s trial supports β amyloid origin of
Toronto Star – "High hopes new drug could be a ‘game changer’ against
W Radio (en español) – “Fármaco para el Alzhéimer va a estar disponible a la
venta en unos años: Stephen Salloway”
||Alzforum.org - "Coming to a Center New You: GAP & EPAD to Revamp Alzheimer’s Trials" - This three-part story discusses how two of the largest Alzheimer’s disease (AD) reform initiatives, GAP & EPAD, are leading the worldwide effort to revamp how clinical trials recruit potential participants and the plan to evaluate more AD investigational drugs in a more timely and cost effective manner. Their integrated approach is focused on streamlining communication and procedures among pharmaceutical companies, academics and even individual governments.
||The Today Show - "New Alzheimer’s Disease Drug May Help People at Risk" Dr. Reisa Sperling, lead investigator for the A4 study in Boston, talks with Maria Shriver about how the study is investigating a new drug aimed at preventing people from developing a buildup of amyloid protein in the brain, which is associated with Alzheimer’s disease.
||WJAR Channel 10 News - "Alzheimer's disease prevention research" Dr. Stephen Salloway discusses a new partnership with the Brain Health Registry and how it can help direct people to participate in prevention trials, such as GeneMatch, especially if there is a family history of Alzheimer’s like Paul Cote’s family.
||WJAR Channel 10 News - "Alzheimer's end-of-life study" One of the program’s most highly altruistic trials, the A16 Autopsy Tau Imaging trial, is currently enrolling with the goal of developing a new diagnostic brain scan.
||Convergence RI - "Rhode Island emerges as a key hub of Alzheimer’s research" Dr. Stephen Salloway discusses how public-private collaborations are the future for treating and preventing Alzheimer’s by 2025.
||Providence Journal - "Help Defeat Alzheimer's" Butler and Rhode Island Hospitals are leading the state in a nationwide study that aims to delay or prevent Alzheimer’s disease in America’s aging population.
||Butler Enrolls First Participant in National Landmark Alzheimer's Study Designed to prevent memory loss, the "A4 Study" (Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease Study) is seeking to enroll 1,000 healthy adults who are at risk for developing Alzheimer's disease but show no outward signs of the disease. Press release
||Associated Press - "Healthy Seniors Tested in Bid to Block Alzheimer's" Researchers have started enrolling volunteers in the A4 Study, including Peter Bristol whose family has been affected by this disease two-fold.
||WJAR Channel 10 News - "Alzheimer's Disease Prevention Trial" NBC’s news affiliate covers the story of Peter Bristol as he becomes the first patient to receive treatment in the A4 Study being conducted at Butler Hospital in partnership with National Institutes of Health (NIH) and Eli Lilly.
||Rhode Island Public Radio - "Butler Kicks Off Alzheimer's Prevention Trial" Butler Hospital begins enrollment of a national landmark trial, the A4 Study, that tests a specific drug’s potential to help prevent Alzheimer’s disease.
||Deep Brain Stimulation Surgery for Alzheimer's Disease Geraldine Paquin is about to embark on uncharted waters undergoing deep brain stimulation (DBS) for Alzheimer's disease. Learn more DBS for Alzheimer's about from WJAR 10's Barbara Morse Silva on Health Check 10.
||New Deep Brain Stimulation Study for Alzheimer's Disease Butler Hospital's Memory & Aging Program, in collaboration with Rhode Island Hospital, is testing deep brain stimulation for Alzheimer's disease.
||Butler Research Improves Diagnostic Tool for Alzheimer's Disease Research conducted by Butler Hospital's Memory & Aging Program contributes to major diagnostic advance in Alzheimer's disease using Amyvid, recently approved by U.S. Food and Drug Administration.